Stock CATX PERSPECTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
1.5 USD -0.66% Intraday chart for Perspective Therapeutics, Inc. -6.25% +273.13%
May. 24 Perspective Therapeutics Prices $80 Million Share, Warrant Offering MT
May. 15 Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Perspective Therapeutics Prices $80 Million Share, Warrant Offering
MT
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GL
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
AQ
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
AQ
Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises
MT
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
AQ
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
RBC Starts Perspective Therapeutics With Outperform Rating, $3 Price Target
MT
Cantor Fitzgerald Starts Perspective Therapeutics With Overweight Rating
MT
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
AQ
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
GL
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
GL
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
AQ
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry
CI
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
CI
Perspective Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.